Scope and Claims Analysis for US Patent 12,589,069 (Loteprendol Etabonate Ophthalmic Suspension: Milled Particle Size + Polycarbophil/HPmC Stabilized Vehicle)

US 12,589,069 is a composition-of-matter focused ophthalmic suspension patent centered on loteprednol etabonate as milled submicron particles combined with a specific suspending/stabilizing vehicle system: polycarbophil (carboxyvinyl polymer) plus hydroxypropylmethyl cellulose (HPMC, including designated grades E3LV and E4M) and, in dependent claims, optional nonionic cellulose/stabilizer and surfactant (poloxamer 407). The patent also adds performance durability limits (storage stability at 1 to 2 years; particle size retention after accelerated storage) and breadth of coverage through particle-size distributions (Dv50 and Dv90 constraints) and formulation add-ins (preservative, chelator, tonicity agents, buffer, humectants).

For licensing, generic-competition risk assessment, or freedom-to-operate design, the enforceable claim core is not “loteprednol etabonate suspension” generally. It is a narrow vehicle + particle size architecture: milled loteprednol etabonate with Dv50 < 1 μm, suspended in a system where polycarbophil is present at 0.1–0.5 wt% and HPMC is present at 0.1–0.5 wt% with explicit linkage of HPMC to nonionic cellulose derivative hydroxypropylmethyl cellulose.

What is the independent claim scope of US 12,589,069?

Claim 1 sets the center of gravity. It covers an ophthalmic suspension defined by (i) particle milling/size limits, (ii) a specific suspending polymer, (iii) a specific particle size stabilizer (HPMC), and (iv) defined drug and excipient concentration ranges.

Claim 1 key limitations (composition scope)

A. Ophthalmic suspension form

“An ophthalmic suspension comprising an ophthalmic active ingredient suspended in a formulation vehicle.”

B. Drug identity

“the ophthalmic active ingredient is loteprednol etabonate.”

C. Drug particle size (distribution limits)

Loteprednol etabonate “is present as milled particles that have Dv50 < 1 μm.”

This is the primary physical constraint. Claim 4, 10, and 11 further narrow Dv90 and add dual thresholds.

D. Vehicle system: suspending agent

“formulation vehicle comprises a suspending agent comprising … polycarbophil.”
Polycarbophil concentration: 0.1–0.5 wt%.

E. Vehicle system: particle size stabilizer

“particle size stabilizing agent comprising … a non-ionic cellulose derivative”
Non-ionic cellulose derivative is explicitly “hydroxypropylmethyl cellulose.”
HPMC concentration: 0.1–0.5 wt%.

F. Drug concentration

Loteprednol etabonate at “about 0.38 wt %.”

What claim 1 does not require (but the patent may cover via dependents)

Claim 1 does not require poloxamer 407.
Claim 1 does not require benzalkonium chloride or borate buffer.
Claim 1 does not require storage-stability durations; that is covered in Claims 2 and 3.
Claim 1 does not require specific HPMC grades (E3LV/E4M), though dependents do.

Practical implication for design-around

To avoid literal infringement of Claim 1, a product generally must break at least one of the critical axes:

Do not use loteprednol etabonate milled to Dv50 < 1 μm.
Do not use polycarbophil in the claimed range.
Do not use HPMC as the particle size stabilizer (or do not use it in the claimed 0.1–0.5 wt% range).
Do not match the loteprednol etabonate concentration of about 0.38 wt%.

Which dependent claims narrow particle size distributions (Dv90) and how broad is that coverage?

Claims 4, 10, and 11 introduce Dv90 thresholds and dual metric constraints that can materially reduce design-around feasibility for “low Dv50 but higher Dv90” products.

Dv90-focused dependents

Claim 4: Dv90 < 5 μm.
Claim 10: Dv90 < 3 μm.
Claim 11: Dv90 < 3 μm AND Dv50 < 0.6 μm.

How this shifts infringement risk

If a candidate formulation matches Claim 1 (Dv50 < 1 μm), it can still avoid Claims 4/10/11 if its Dv90 is above those thresholds or if Dv50 is ≥ 0.6 μm (for Claim 11).
Claim 11 is the most restrictive: it requires both high fineness (Dv50 < 0.6 μm) and tight tail control (Dv90 < 3 μm).

Does US 12,589,069 claim storage stability performance, or is it only composition?

The patent claims performance tied to storage stability and particle-size retention after accelerated aging.

Storage stability dependents

Claim 2: “storage stable for at least one year.”
Claim 3: “storage stable for at least two years.”

Accelerated stability / particle growth limit

Claim 12: upon storage at 40°C for 8.5 months, particles “subsequently have a volume mean diameter ≤ 1.23 μm” measured by light diffraction.

How these claims affect enforcement

These dependent claims are valuable in disputes because they convert “formulation meets size” into “formulation maintains the size profile after stress.”
For a generic or competitor, evidentiary exposure increases if testing under the claimed conditions yields particle growth above the threshold.

What vehicle formulation details are protected (polycarbophil + HPMC grades E3LV/E4M; poloxamer 407)?

The patent makes the vehicle architecture explicit, including polymer class, specific stabilizer family, and even named HPMC grades.

HPMC grade specificity

Claim 5: HPMC is “hydroxypropylmethyl cellulose E3LV” at ≥ 0.25%.
Claim 6: HPMC is “hydroxypropylmethyl cellulose E4M.”
Claim 8: HPMC is E3LV or E4M at 0.15–0.25 wt%.
Claim 9: HPMC is E4M at 0.15–0.25 wt%.

These grades can matter because they imply viscosity/functional differences that affect suspension rheology and particle stabilization. If a competitor uses HPMC but selects a different grade not falling into the literal dependent claim language, it may still infringe Claim 1 if the general HPMC definition and concentration ranges are met.

Surfactant limitation

Claim 7: poloxamer nonionic surfactant comprises “poloxamer 407.”
Claim 13: adds poloxamer at 0.1–1.0 wt% but only as a dependent that builds on Claim 1.

Suspending agent is fixed in the patent’s independent structure

Polycarbophil is the suspending agent in Claim 1 and is already concentration-limited to 0.1–0.5 wt%.

What excipient package is covered (benzalkonium chloride, edetate, NaCl, poloxamer, humectants, borate buffer)?

Claims 13 and 14 define a broader “typical ophthalmic” excipient package layered on top of Claim 1. These can be critical for litigating formulation similarity in Paragraph IV or non-infringement defenses.

Claim 13 excipient ranges (dependent on Claim 1)

Benzalkonium chloride: 0.001–0.01 wt%
Edetate disodium dihydrate: 0.01–0.1 wt%
Sodium chloride: 0.01–0.1 wt%
Poloxamer nonionic surfactant: 0.1–1.0 wt%
Glycerin and propylene glycol: 0.1–2 wt%

Claim 14 buffer

Borate buffer: 0.01–1 wt%

Claim 17/18 mirror the excipient package in method claims

Claims 17 and 18 repeat these ranges in the method-of-treating context.

Is this a method-of-use patent, a formulation patent, or both?

Both. The patent contains:

Composition claim(s): Claim 1 and its dependents 2–14 (with formulation, particle size, storage stability, and excipient package).
Method-of-use claim(s): Claims 15–20.

Method-of-use claim structure (Claim 15)

Administering to treat an ophthalmic inflammatory condition.
The administered formulation must have the same core defining structure as Claim 1:
- loteprednol etabonate as milled particles with Dv50 < 1 μm
- vehicle with polycarbophil + HPMC (nonionic cellulose derivative, hydroxypropylmethyl cellulose)
- loteprednol etabonate about 0.38 wt%
- polycarbophil 0.1–0.5 wt%
- HPMC 0.1–0.5 wt%

Method dependents

Claim 16: Dv90 < 5 μm and Dv50 < 1 μm
Claim 17: adds Claim 13 excipient ranges
Claim 18: adds borate buffer
Claim 19: HPMC E3LV or E4M at 0.15–0.25 wt%
Claim 20: HPMC E4M at 0.15–0.25 wt%

Enforcement implication: A formulation that does not infringe the composition claims can still potentially be swept by the method claims only if it is administered in a way that meets the method’s formulation limitations. In practice, method-of-use claims are less useful for post-marketing design-around than composition claims unless the product’s label or indication is directly tied to the patented method and the accused product is close.

How many distinct claim “buckets” does US 12,589,069 cover?

The 20 claims cluster into 5 actionable protection buckets:

Core composition bucket (Claim 1)
- loteprednol etabonate + Dv50 < 1 μm + polycarbophil (0.1–0.5 wt%) + HPMC (0.1–0.5 wt%) + about 0.38 wt% drug.
Particle size distribution bucket
- Dv90 < 5 μm (Claim 4)
- Dv90 < 3 μm (Claims 10)
- Dv90 < 3 μm and Dv50 < 0.6 μm (Claim 11)
Stability/performance bucket
- storage stable ≥ 1 year (Claim 2)
- storage stable ≥ 2 years (Claim 3)
- 40°C 8.5 months then volume mean diameter ≤ 1.23 μm (Claim 12)
Vehicle grade and additive bucket
- HPMC grade and concentration constraints (Claims 5, 6, 8, 9)
- poloxamer 407 (Claim 7)
Typical ophthalmic excipient package bucket
- preservative, chelator, tonicity, surfactant concentration, humectants (Claim 13)
- borate buffer (Claim 14)
- mirrored in method claims (Claims 17–18)

This claim segmentation matters because infringement arguments tend to isolate which bucket is met by a candidate product.

What does the claim language imply for generic entry and “label-only” challenges?

Because the independent claim is a tight formulation with particle-size metrics, a generic cannot rely on label changes alone. To avoid infringement, challengers must modify one or more formulation parameters that are explicitly claimed.

Highest-risk matching parameters

loteprednol etabonate at about 0.38 wt%
Dv50 < 1 μm milled particle specification
polycarbophil 0.1–0.5 wt%
hydroxypropylmethyl cellulose 0.1–0.5 wt% as the particle size stabilizer

Secondary risk parameters

Dv90 < 5 or < 3 μm
HPMC specific grades (E3LV/E4M) and concentration sub-ranges (0.15–0.25; ≥0.25 for E3LV)
poloxamer 407 inclusion
excipient ranges (benzalkonium chloride, borate buffer, etc.)
storage stability/performance tests

What is the likely defensible “design-around map” under the claim set?

Below is a practical infringement-avoidance map consistent with the claim structure (not legal advice, only technical alignment with claim elements).

To avoid Claim 1 (composition)

A candidate product must ensure at least one of:

Dv50 ≥ 1 μm for the loteprednol etabonate particles
polycarbophil is absent or outside 0.1–0.5 wt%
HPMC is absent or outside 0.1–0.5 wt% (or not used as the particle size stabilizing agent)
loteprednol etabonate not present at about 0.38 wt%

To avoid the narrower dependents even if Claim 1 is met

Increase Dv90 above 5 μm (Claim 4) or above 3 μm (Claims 10/11)
Ensure Dv50 ≥ 0.6 μm (to avoid Claim 11)
Fail to meet storage stability durations if those become tested in litigation (Claims 2/3) or exceed the post-40°C particle-size limit (Claim 12)
Use different HPMC grade that is not E3LV/E4M where dependent claims demand grade-specific language
Avoid poloxamer 407
Use excipients outside the dependent ranges or a different buffer system to avoid Claims 13/14

How strong is the protection relative to typical ophthalmic suspension IP patterns?

Strong on specificity; medium on breadth. The patent is not a broad “loteprednol etabonate suspension” claim. It is a detailed, multi-parameter formulation with explicit particle size and vehicle definitions plus performance constraints.

Strength indicators within the claims:

Numeric thresholds (Dv50, Dv90, wt% ranges).
Specific polymer architecture: polycarbophil + HPMC as stabilizer.
Explicit named HPMC grades in multiple dependents.
Stability assertions with test condition (40°C/8.5 months) and particle-size result.

Breadth limitations:

Tight coupling of vehicle components to particle size requirements.
Many key features are concentration and distribution constrained, leaving fewer degrees of freedom for design-around while still producing a suspension that remains clinically comparable.

Key claim chart (US 12,589,069)

Claim	Coverage focus	Hard numeric/identity elements
1	Core composition	Loteprednol etabonate; Dv50 < 1 μm; loteprednol etabonate ~0.38 wt%; polycarbophil 0.1–0.5 wt%; HPMC 0.1–0.5 wt% (non-ionic cellulose derivative = HPMC)
2	Storage stability	storage stable ≥ 1 year
3	Storage stability	storage stable ≥ 2 years
4	Particle tail	Dv90 < 5 μm
5	HPMC grade + concentration	HPMC E3LV; ≥0.25%
6	HPMC grade	HPMC E4M (grade-specific)
7	Surfactant	poloxamer 407 (as poloxamer nonionic surfactant)
8	HPMC grade + narrower band	HPMC E3LV or E4M; 0.15–0.25 wt%
9	HPMC grade + narrower band	HPMC E4M; 0.15–0.25 wt%
10	Particle tail + tighter	Dv90 < 3 μm
11	Tightest particle control	Dv90 < 3 μm AND Dv50 < 0.6 μm
12	Accelerated stability via particle retention	40°C 8.5 months then volume mean diameter ≤ 1.23 μm (light diffraction)
13	Full excipient package	BAK 0.001–0.01; edetate 0.01–0.1; NaCl 0.01–0.1; poloxamer 0.1–1.0; glycerin + propylene glycol 0.1–2
14	Buffer	borate buffer 0.01–1
15	Method of use	administer treating ophthalmic inflammatory condition with a Claim 1 formulation
16	Method particle constraints	Dv90 < 5 μm and Dv50 < 1 μm
17	Method excipient package	adds Claim 13 excipients/ranges
18	Method buffer	adds borate buffer per Claim 14
19	Method HPMC grades band	HPMC E3LV or E4M at 0.15–0.25
20	Method HPMC grade	HPMC E4M at 0.15–0.25

What patent landscape conclusions can be drawn from the claim set alone?

With only the claim text provided, enforceability and landscape read-through are limited to structural coverage inside the patent. The claim set indicates a patent intended to block close “same-bucket” formulations rather than a broad formulation class.

Most likely competitive pressure point

Companies pursuing “equivalent” ophthalmic suspensions with loteprednol etabonate will face the toughest overlap when they adopt:

submicron milled drug particle distributions (Dv50 < 1 μm),
polycarbophil suspension,
HPMC stabilization (especially E3LV/E4M),
and a package of standard ophthalmic excipients within the given ranges.

Most likely path to avoid infringement

Increase particle size distribution metrics outside claimed thresholds, change the vehicle polymer/stabilizer system, or modify polymer concentration bands.

Key Takeaways

US 12,589,069 protects a specific ophthalmic suspension architecture: loteprednol etabonate milled to Dv50 < 1 μm suspended in polycarbophil (0.1–0.5 wt%) with HPMC (0.1–0.5 wt%) as the particle size stabilizer, with drug concentration “about 0.38 wt%.”
Dependent claims tighten particle distribution using Dv90 < 5 μm (Claim 4), Dv90 < 3 μm (Claim 10), and Dv90 < 3 μm plus Dv50 < 0.6 μm (Claim 11).
The patent also claims performance durability: ≥1 year (Claim 2), ≥2 years (Claim 3), and an accelerated condition limit at 40°C for 8.5 months with subsequent volume mean diameter ≤ 1.23 μm (Claim 12).
Vehicle grade matters: multiple dependents specify HPMC E3LV and HPMC E4M with concentration bands.
A broader ophthalmic excipient package is captured in dependent Claims 13–14 (preservative, chelator, tonicity, poloxamer range, humectants, borate buffer), and these excipient/range limitations are repeated in method-of-use claims.
The enforceable scope is formulation-centric; generic or competitor products can’t rely on indication-only differentiation if they meet the claimed formulation and particle-size metrics.

FAQs

1) What single parameter is most likely to determine infringement of US 12,589,069?
Dv50 < 1 μm for loteprednol etabonate within the specified vehicle and concentration ranges of Claim 1.

2) Can a product infringe dependent particle-size claims even if it avoids Claim 1?
No. Dependent claims require the limitations of Claim 1 plus added restrictions, so avoiding Claim 1 typically avoids all dependent claim sets.

3) What is the tightest particle specification in the patent?
Claim 11: Dv90 < 3 μm and Dv50 < 0.6 μm.

4) Does the patent require poloxamer 407?
Only in Claim 7 and as part of the broader excipient range package in Claim 13; it is not required by Claim 1.

5) Are method-of-use claims broader than composition claims?
They track the same formulation definitions from Claim 1, so they do not expand beyond the composition framework.

References (APA)

United States Patent 12,589,069. (Claims provided in prompt text).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	LOTEMAX SM	loteprednol etabonate	GEL;OPHTHALMIC	208219-001	Feb 22, 2019	AB	RX	Yes	Yes	12,589,069	⤷ Start Trial	Y			TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Summary for Patent: 12,589,069